AI-powered neuroimaging biomarkers for Neurology and Psychiatry
What is the problem?
The diagnosis of neurologic and psychiatric disorders still relies mostly on clinicians’ subjective impression of the patients’ clinical history, human eye-inspection of brain scans and memory.
Neuropsychiatric disorders such as Alzheimer’s and Parkinson’s are particularly difficult to diagnose, especially in its early stages, as symptoms are mild, unspecific and brain changes still subtle. In fact, at the time of the first appointment, 30% of Alzheimer’s and about 10% of Parkinson’s patients are misdiagnosed.
An incorrect or delayed diagnosis entails late and potentially harmful treatments and unnecessary costs.
We support clinicians for a more timely and confident diagnosis.
By applying artificial intelligence to brain scan data (in specific, magnetic resonance imaging), NeuroPsyCAD is able to recognize disease ‘signatures’ in a new patient’s brain scan.